Literature DB >> 7035561

Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B.

R A Insel, P W Anderson.   

Abstract

Escherichia coli K100 is known to induce antibodies cross-reactive with the capsular polysaccharide (CP) of Haemophilus influenzae b (Hib); the cross-immunogenicity is found consistently in a number of mammalian species including man. We have studied the reciprocal cross-immunogenicity of Hib or its purified CP in man. Of 25 adults and 13 children responding to systemic immunization with Hib CP, only four and four, respectively, made K100 CP cross-reactive antibody, determined by radioantigen-binding inhibition. The detection of preimmunization cross-reactive antibody was not statistically predictive of induction of postimmunization cross-reactive antibody. Cross-reactive antibody was detected in only one of 11 children making an anticapsular response to Hib systemic infection and two of four children responding to asymptomatic nasopharyngeal colonization. In contrast, cross-reactivity was detected in the naturally occurring anti-Hib-CP antibody of 27 of 42 children. Thus, humans responding to Hib or its CP often do not make antibody to the K100-cross-reactive determinant(s), implying that the cross-reactive natural antibodies frequently seen in children must have a stimulus other than Hib.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7035561

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Structural requirements of the major protective antibody to Haemophilus influenzae type b.

Authors:  L Hougs; L Juul; A Svejgaard; T Barington
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Immune response to Haemophilus influenzae type b vaccination in patients with chronic renal failure.

Authors:  Nicole Hawdon; Eli B Nix; Raymond S W Tsang; Garry Ferroni; William G McCready; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.

Authors:  J McVernon; M E Ramsay; A R McLean
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

4.  Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era.

Authors:  Eli B Nix; Nicole Hawdon; Sean Gravelle; Birubi Biman; Malcolm Brigden; Saleem Malik; William McCready; Garry Ferroni; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

Review 5.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations.

Authors:  E E Adderson; P G Shackelford; R A Insel; A Quinn; P M Wilson; W L Carroll
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  An idiotypic marker associated with a germ-line encoded kappa light chain variable region that predominates the vaccine-induced human antibody response to the Haemophilus influenzae b polysaccharide.

Authors:  A H Lucas; R J Langley; D M Granoff; M H Nahm; M Y Kitamura; M G Scott
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

8.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

9.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

10.  Selective antibody deficiency to Haemophilus influenzae type B capsular polysaccharide vaccination in children with recurrent respiratory tract infection.

Authors:  H G Herrod; S Gross; R Insel
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.